Clinically used drug arsenic trioxide targets XIAP and overcomes apoptosis resistance in an organoid-based preclinical cancer model
Shi L, Lu J, Xia X, Liu X, Li H, Li X, Zhu J, Li X, Sun H, Yang X. Clinically used drug arsenic trioxide targets XIAP and overcomes apoptosis resistance in an organoid-based preclinical cancer model. Chem Sci. 2024 May 3;15(22):8311-8322. doi: 10.1039/d4sc01294a. PMID: 38846391; PMCID: PMC11151819.
Like
Be the first to like this
Please sign in or register for FREE
If you are a registered user on WORC.Community, please sign in